Atossa Therapeutics, Inc.
ATOS
$1.88
$0.116.22%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
6/25/2026
-
Simply Wall St
6/12/2026
-
PR Newswire
6/11/2026
-
SeekingAlpha.com: All News
6/11/2026
-
Seeking Alpha - Healthcare
6/11/2026
-
TipRanks: TheFly
6/11/2026
-
TipRanks: TheFly
6/11/2026
-
PR Newswire
6/10/2026
-
Proactive Investors - UK
5/27/2026
-
PR Newswire
5/20/2026
-
PR Newswire
5/20/2026
-
Seeking Alpha: Transcripts
5/20/2026
-
SeekingAlpha
5/14/2026
-
GuruFocus
5/14/2026
-
PR Newswire
Atossa Genetics (NASDAQ:ATOS) Announces Quarterly Earnings Results, Misses Expectations By $0.12 EPS
5/10/2026
-
The Cerbat Gem
5/9/2026
-
TipRanks Financial Blog
5/8/2026
-
TipRanks Financial Blog
5/8/2026
-
Seeking Alpha - Healthcare
5/8/2026
-
PR Newswire
5/6/2026
-
PR Newswire
5/5/2026
-
The Cerbat Gem
5/4/2026
-
Stocktwits News Feed
5/4/2026
-
PR Newswire
3/26/2026
-
TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
Filings
Filing Date
Friday, May 8, 2026
Period Date
Tuesday, March 31, 2026
Next Filing
Week of Aug 10 and 14 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
206 588 0256
Address
448 NW Market Street
Seattle, WA 98107
Seattle, WA 98107
Country
Year Founded
Business Description
Sector
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is...
more